Hematologic Malignancies Articles

High Response Rate, MRD Negativity Confirmed for Venetoclax in CLL
Treatment with the BCL-2 inhibitor venetoclax (Venclexta) led to negative minimal residual disease (MRD) status in 40% of evaluable patients with relapsed/refractory chronic lymphocytic leukemia.
Observation After Diagnosis Viable Strategy for Some Patients With MCL
Some patients with mantle cell lymphoma can delay treatment without experiencing negative outcomes, according to findings from a population-based study.
Update Sustains Tisagenlecleucel Activity in Pediatric ALL
Tisagenlecleucel (Kymriah) induced a complete remission with complete or incomplete hematologic recovery in 83% of pediatric, adolescent, and young adult patients with acute lymphoblastic lymphoma.
Expert Discusses Strategies for Advancing Pediatric ALL Care
The effort to improve outcomes in pediatric acute lymphoblastic leukemia should follow insight provided by next-generation sequencing and appropriate use of minimal residual disease criteria.
EU Approves Midostaurin for AML, Advanced Systemic Mastocytosis
The European Commission has approved midostaurin (Rydapt) for adults with newly diagnosed FLT3-positive acute myeloid leukemia and advanced systemic mastocytosis.
Dramatic Improvement in NHL Outcomes With CAR T-Cell Versus Standard Therapy
Treatment with the autologous anti-CD19 CAR T-cell therapy axicabtagene ciloleucel significantly improved outcomes in refractory non-Hodgkin lymphoma compared with standard therapies.
CAR T-Cell Therapy Active in High-Risk, Refractory CLL
Patients with refractory chronic lymphocytic leukemia achieved a high-response rate with CD19-targeted CAR T-cell therapy JCAR014. 
Maintenance Rituximab Post-ASCT Associated With Improved OS in MCL
Patients who received maintenance therapy with rituximab (Rituxan) following autologous stem cell transplantation as treatment for mantle cell lymphoma had a survival advantage, according to results from a retrospective single-center study.
Ibrutinib Highly Active Against MCL in Pooled Analysis
In a pooled analysis, investigators determined that ibrutinib (Imbruvica) induced an objective response rate of 66% in patients with mantle cell lymphoma.
Venetoclax Combination Improves PFS in Phase III CLL Trial
The combination of venetoclax and rituximab significantly improved progression-free survival compared with rituximab plus bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL),
Publication Bottom Border
Border Publication